Want to see IN:CIPLA full AI Analyst Report?
CIPLA Stock Chart & Stats
₹1410.90
₹4.40(0.31%)
At close: 4:00 PM EDT
₹1410.90
₹4.40(0.31%)
Day’s Range― - ―
52-Week Range₹1,165.55 - ₹1,672.20
Previous CloseN/A
Volume1.16M
Average Volume (3M)41.77K
Market Cap
₹1.16T
Enterprise Value₹895.23K
Total Cash (Recent Filing)₹100.28B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)34.3
Beta0.56
Next Earnings
Oct 29, 2026EPS Estimate
11.75Next Dividend Ex-DateN/A
Dividend Yield2.03%
Share Statistics
EPS (TTM)41.74
Shares Outstanding807,853,150
10 Day Avg. Volume63,362
30 Day Avg. Volume41,773
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.87
Price to Sales (P/S)3.51
P/FCF Ratio39.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,474.75Price Target Upside4.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)51.51
Revenue Forecast (FY)₹309.65B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and growing equity and assets provide financial flexibility. This supports continued investment in products, manufacturing and market expansion while reducing exposure to financing stress across the operating cycle.
Positive Cash GenerationConsistent positive operating and free cash flow gives Cipla internally generated funding for research, capacity, acquisitions and shareholder returns. Although conversion varies, the underlying cash-generation record supports business resilience.
Diversified Pharmaceutical Portfolio And ReachBroad therapeutic coverage, branded formulations and generics across domestic and overseas markets diversify revenue sources. Respiratory, chronic-care, injectable and inhalation products also provide multiple avenues for durable product growth.
Bears Say
Sharp FY2026 Revenue DeclineThe latest revenue contraction interrupts Cipla’s prior growth trajectory and raises questions about product demand, competitive intensity or portfolio mix. Sustained weakness would limit operating leverage and reduce resources available for expansion.
Margin CompressionLower gross and net margins indicate that profitability has become less durable than in FY2024–FY2025. If pricing pressure, mix changes or cost inflation persist, weaker margins could constrain earnings and reinvestment capacity.
Uneven Cash ConversionStrong absolute cash flow is tempered by inconsistent conversion from accounting profit, suggesting working-capital or cash-timing variability. Persistent divergence could make funding and earnings quality less predictable despite the low-debt balance sheet.
Cipla Ltd News
CIPLA FAQ
What was Cipla Ltd’s price range in the past 12 months?
Cipla Ltd lowest stock price was ₹1165.55 and its highest was ₹1672.20 in the past 12 months.
What is Cipla Ltd’s market cap?
Cipla Ltd’s market cap is ₹1.16T.
When is Cipla Ltd’s upcoming earnings report date?
Cipla Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 68 days.
How were Cipla Ltd’s earnings last quarter?
Cipla Ltd released its earnings results on Jul 23, 2026. The company reported ₹9.76 earnings per share for the quarter, missing the consensus estimate of ₹10.618 by -₹0.858.
Is Cipla Ltd overvalued?
According to Wall Street analysts Cipla Ltd’s price is currently Undervalued.
Does Cipla Ltd pay dividends?
Cipla Ltd pays a Notavailable dividend of ₹13 which represents an annual dividend yield of 2.03%. See more information on Cipla Ltd dividends here
What is Cipla Ltd’s EPS estimate?
Cipla Ltd’s EPS estimate is 11.75.
How many shares outstanding does Cipla Ltd have?
Cipla Ltd has 807,853,150 shares outstanding.
What happened to Cipla Ltd’s price movement after its last earnings report?
Cipla Ltd reported an EPS of ₹9.76 in its last earnings report, missing expectations of ₹10.618. Following the earnings report the stock price went down -1.509%.
Which hedge fund is a major shareholder of Cipla Ltd?
Currently, no hedge funds are holding shares in IN:CIPLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cipla Ltd
Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
CIPLA Stock 12 Month Forecast
Average Price Target
₹1,474.75
▲(4.53% Upside)
Technical Analysis
Abbott India Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Marksans Pharma Limited
―
PFIZER LIMITED
―








